Filing Flows › C4 Therapeutics (CCCC) › Q1 2026
C4 Therapeutics (CCCC) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
C4 Therapeutics (CCCC) reported revenue of $6.2M for the first quarter 2026 (Q1 2026), -15% from a year earlier and -44% from the quarter before. Operating margin was -451.6%, net loss $25.1M (408.5% of revenue).
C4 Therapeutics, Q1 2026: revenue $6.2M (-15% year over year), operating margin -451.6%, net loss $25.1M, operating cash flow −$29.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.2M | -44% | -15% |
| Operating profit | −$27.8M | — | — |
| Net earnings | −$25.1M | — | — |
| Operating cash flow | −$29.9M | — | — |
What changed
Revenue was $6.2M in Q1 2026, down 15% year over year and down 44% from the previous quarter.
Operating costs exceeded revenue by $27.8M, an operating margin of -451.6%. Total costs fell 7% while revenue fell 15%. The quarter ended with a net loss of $25.1M, wider than the previous quarter's $20.5M loss.
Operating cash flow was −$29.9M. Non-cash charges added back $404K of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items used $7.9M. Capital expenditures of $64K exceeded it, leaving free cash flow of −$30.0M.
Questions
What was C4 Therapeutics' revenue in the first quarter 2026?
C4 Therapeutics (CCCC) reported revenue of $6.2M for the first quarter 2026 (Q1 2026), -15% from a year earlier and -44% from the quarter before.
Was C4 Therapeutics profitable in the first quarter 2026?
Operating loss was $27.8M (-451.6% of revenue) and net loss $25.1M.
Source: C4 Therapeutics 10-Q on SEC EDGAR.